Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
03 February 2016Website:
http://www.editasmedicine.comNext earnings report:
02 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Wed, 03 Jul 2024 20:53:40 GMTDividend
Analysts recommendations
Institutional Ownership
EDIT Latest News
Editas (EDIT) reports positive new safety and efficacy data from the RUBY and EdiTHAL studies evaluating its investigational gene therapy, reni-cel, for SCD and TDT, respectively.
Editas Medicine, Inc. will be holding a conference call and webcast on May 8, 2024, at 8:00 a.m. ET to discuss first quarter 2024 results and provide a corporate update.
Editas (EDIT) lacks the ideal mix of factors needed for a potential earnings surprise in its next report. Be ready for the important projections.
Editas (EDIT) reported earnings 30 days ago. What's next for the stock?
Editas Medicine just successfully navigated a key regulatory issue. Its reni-cel candidate now has a clearer path through its clinical trials.
Editas Medicine has recorded solid progress with its leading candidate. The biotech's financial position looks strong, given its clinical-stage status.
Editas Medicine's fourth-quarter results contained surprises. Financial results were better than expected.
Editas (EDIT) reports better-than-expected fourth-quarter 2023 results as both earnings and revenues beat estimates, driven by collaboration revenues received from Vertex. The stock gains 25%.
Editas Medicine, Inc. (EDIT) Q4 2023 Earnings Call Transcript
Editas Medicine (EDIT) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.52. This compares to loss of $0.88 per share a year ago.
What type of business is Editas Medicine?
Editas Medicine, Inc. is a pharmaceutical company based in Cambridge, Massachusetts, developing treatment methods based on CRISPR-Cas9 gene editing technology. Editas Medicine, Inc. was founded in 2013. Editas Medicine is a leading genome editing company at the clinical stage, working on the development of potentially transformative genomic medicines for a wide range of serious diseases. The company has developed its own genome editing platform based on CRISPR technology. Editas Medicine's main developments are in the field of eye diseases and engineered cell therapies for the treatment of hemoglobinopathies and cancer.
What sector is Editas Medicine in?
Editas Medicine is in the Healthcare sector
What industry is Editas Medicine in?
Editas Medicine is in the Biotechnology industry
What country is Editas Medicine from?
Editas Medicine is headquartered in United States
When did Editas Medicine go public?
Editas Medicine initial public offering (IPO) was on 03 February 2016
What is Editas Medicine website?
https://www.editasmedicine.com
Is Editas Medicine in the S&P 500?
No, Editas Medicine is not included in the S&P 500 index
Is Editas Medicine in the NASDAQ 100?
No, Editas Medicine is not included in the NASDAQ 100 index
Is Editas Medicine in the Dow Jones?
No, Editas Medicine is not included in the Dow Jones index
When does Editas Medicine report earnings?
The next expected earnings date for Editas Medicine is 02 August 2024